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dexamethasone 21-phosphate reduced the efficacy of cef-
tazidime in vivo. In conclusion, demonstration of an effec-
tive immunosuppressant regimen can improve the specific-
ity and broaden the applications of the G. mellonella model 
to address key questions regarding infection.
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Introduction
Globally, multidrug-resistant (MDR) Gram-negative bacte-
ria are a major cause of hospital-acquired infections and are 
considered an urgent public health threat [1]. The major-
ity of these infections are either pneumonia, bloodstream 
or urinary tract infections and are associated with invasive 
medical devices or surgical procedures and effect patients 
that are already debilitated or immunocompromised 
(reviewed in [2]). With increasing incidence of resistance 
to carbapenems, the antibiotics of ‘last-resort’, only a lim-
ited number of antibiotic treatments are available for some 
MDR bacteria [3] resulting in high mortality rates [4].
In the USA, the most common MDR bacteria associ-
ated with hospital-acquired infections are Klebsiella pneu-
moniae and Escherichia coli [1]. MDR strains of these 
organisms initially acquired a variety of extended-spec-
trum β-lactamases (ESBLs) that rendered them resistant 
to cephalosporin antibiotics resulting in increased use of 
carbapenems. Subsequently, this selected for the acquisi-
tion of carbapenemases rendering strains resistant to this 
class of drugs also. In the UK, the first strain of K. pneu-
moniae with resistance to carbapenems due to expression 
of the K. pneumoniae carbapenemase 3 enzyme (KPC-3) 
Abstract The aim was to evaluate whether immuno-
suppression with dexamethasone 21-phosphate could be 
applied to the Galleria mellonella in vivo infection model. 
Characterised clinical isolates of Escherichia coli or Kleb-
siella pneumoniae were employed, and G. mellonella lar-
vae were infected with increasing doses of each strain to 
investigate virulence in vivo. Virulence was then compared 
with larvae exposed to increasing doses of dexamethasone 
21-phosphate. The effect of dexamethasone 21-phosphate 
on larval haemocyte phagocytosis in vitro was determined 
via fluorescence microscopy and a burden assay measured 
the growth of infecting bacteria inside the larvae. Finally, 
the effect of dexamethasone 21-phosphate treatment on the 
efficacy of ceftazidime after infection was also noted. The 
pathogenicity of K. pneumoniae or E. coli in G. mellonella 
larvae was dependent on high inoculum numbers such that 
virulence could not be attributed specifically to infection by 
live bacteria but also to factors associated with dead cells. 
Thus, for these strains, G. mellonella larvae do not consti-
tute an ideal infection model. Treatment of larvae with dex-
amethasone 21-phosphate enhanced the lethality induced 
by infection with E. coli or K. pneumoniae in a dose- and 
inoculum size-dependent manner. This correlated with pro-
liferation of bacteria in the larvae that could be attributed to 
dexamethasone inhibiting haemocyte phagocytosis and act-
ing as an immunosuppressant. Notably, prior exposure to 
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was reported in 2007 [5]. Also in the UK, concern was first 
raised in 2003 that MDR E. coli expressing the CTX-M-15 
ESBL were increasingly being identified in patients with 
community-acquired urinary tract infections that had no 
previous history of hospitalisation [6]. This spread of MDR 
pathogens into general practice with few treatment options 
represents a serious threat to public health.
Thus, there is clear need to research and develop new 
antibiotics and treatment regimens to combat MDR Gram-
negative infections. To facilitate this process, the use of ani-
mal models to measure efficacy of potential new treatments 
is an indispensable part of the drug discovery pipeline. 
Presently, the majority of novel antimicrobials that are ini-
tially identified in vitro are then tested for efficacy in vivo 
using murine infection models. The problems associated 
with employing mammalian infection models include ethi-
cal issues, high costs and their impracticality for large-scale 
screening of efficacy. Thus, researchers are increasingly 
using alternative infection models such as invertebrates to 
circumvent these issues.
Larvae of the greater wax moth Galleria mellonella 
have been employed as an in vivo model in many investi-
gations of bacterial pathogenicity or efficacy of antibiotic 
treatments (reviewed in [7]). Advantages of G. mellonella 
include: fewer ethical concerns, low cost, precise inocula-
tion of bacteria and/or dosing of drugs, ability to incubate 
larvae at human body temperature and ease of use with 
regard to high-throughput screening of novel treatments 
in vivo. Disadvantages include the reduced complexity of 
the invertebrate immune system compared to mammals due 
to the absence of adaptive immunity, the inability to study 
long-term, chronic infections and the exclusion of patho-
gens that do not display virulence in the larvae.
Galleria mellonella larvae have been used to character-
ise pathogenicity and virulence of K. pneumoniae clinical 
isolates and strains with mutations in known virulence fac-
tor genes [8–10]. Furthermore, G. mellonella was used to 
quantify the efficacy of antibiotics against planktonic or 
biofilm cultures of MDR strains of K. pneumoniae [11]. 
Similar studies with pathogenic E. coli have also been 
undertaken with G. mellonella that have correlated lethal-
ity with specific virulence factors in uropathogenic [12, 13] 
and enteropathogenic isolates [14]. Also, G. mellonella was 
comparable to a murine model for measuring virulence of 
a range of E. coli clinical isolates [15]. Notably, assess-
ment of the inoculum size of K. pneumoniae or E. coli that 
was required to induce significant lethality in G. mellonella 
reveals huge variability between bacterial strains but also 
that the minimum number of bacteria required to cause 
significant larval death, even with the most virulent strains 
tested, was much higher with K. pneumoniae and E. coli 
compared with that required for another Gram-negative 
pathogen Pseudomonas aeruginosa [16, 17].
In this study, the effect of treating G. mellonella larvae 
with a water-soluble derivative of the immunosuppressant 
drug dexamethasone on subsequent susceptibility to infec-
tion by K. pneumoniae and E. coli was evaluated. The aims 
of the study were: (1) to decrease the relatively high inocu-
lum of K. pneumoniae or E. coli cells required to induce a 
lethal infection in G. mellonella larvae to explore whether 
immunosuppression could be employed as a viable route to 
expand use of this model to pathogens that do not display vir-
ulence or induce acute infections in the larvae; (2) to mimic 
the immunosuppressed state that is often a significant factor 
with human patients that suffer from hospital-acquired infec-
tions by K. pneumoniae and E. coli; and finally (3) to assess 
the effect of immunosuppression on the efficacy of antibiotic 
treatment for K. pneumoniae or E. coli infection in vivo.
Materials and methods
Bacteria and growth media
Bacteria were obtained from the National Collection of 
Type Cultures (NCTC) (http://www.hpacultures.org.uk/
collections/nctc.jsp). The K. pneumoniae strains were 
NCTC9633 (type strain) and NCTC13438 (a MDR isolate 
possessing the KPC-3 carbapenemase; [5]), and the E. coli 
strains were NCTC12241 (a control strain for antibiotic 
sensitivity testing) and NCTC13353 (an isolate possessing 
the CTX-M-15 ESBL; [6]). All of these strains are clinical 
isolates. Strains were cultured overnight in Mueller–Hinton 
Broth (MHB; Merck, Darmstadt, Germany) at 37 °C with 
shaking to prepare inocula for in vivo infections.
Reagents and G. mellonella larvae
Unless stated, all chemicals and ceftazidime hydrate were 
purchased from Sigma-Aldrich Ltd (Dorset, UK). Stock 
solutions and sub-stocks of all drugs for use in experiments 
were made in sterile deionised water. G. mellonella larvae 
were purchased from UK Waxworms Ltd (Sheffield, UK).
Galleria mellonella infection model and treatment 
with dexamethasone
This was carried out as previously described [17]. Briefly, 
groups of 15 larvae were infected with variable inocu-
lum sizes of K. pneumoniae or E. coli cells and incubated 
at 37 °C. Larval survival was determined every 24 h for 
96 h in total. Precise numbers of bacterial cells inoculated 
were determined by serial dilution in MHB and plating on 
Nutrient Agar (NA; Merck, Darmstadt, Germany) prior to 
counting colonies after overnight incubation of plates at 
37 °C. Each experiment was repeated at least twice using 
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larvae from different batches. The data from these replicate 
experiments were then pooled, and survival data were plot-
ted using the Kaplan–Meier method and comparisons made 
between groups using the log-rank test. In all comparisons 
to the negative control, it was the uninfected control (rather 
than the unmanipulated control) that was used. In all tests, 
p ≤ 0.05 was considered significant and Holm’s correc-
tion was applied to account for multiple comparisons [18]. 
Heat-killed (98 °C, 15 min) inocula at the highest inoculum 
sizes used were also injected as controls. Heat-killing was 
verified by plating the heated inocula on NA. To identify 
any secreted bacterial virulence factors both heat-killed 
and live inocula were sterile-filtered using Millex 0.22 μM 
syringe-driven filters (Millipore Ltd, Tullagren, Co. Cork, 
Ireland) and the filtrate injected into the larvae.
The effect of exposure to dexamethasone was tested by 
injecting dexamethasone 21-phosphate disodium (50 mg/
mL stock solution in H2O) for variable time periods 
(10 min, 2, 4, 6 and 8 h) or at variable doses (80 or 200 μg 
per larva) prior to infection of larvae with bacteria.
For experiments involving a single dose of ceftazidime, 
the antibiotics were administered 2 h post-infection (p.i).
Galleria mellonella haemolymph burden
Groups of 40 larvae were treated with 200 μg per larva of 
dexamethasone 21-phosphate disodium prior to infection 
with known numbers of K. pneumoniae or E. coli cells and 
incubation at 37 °C. After 5 h incubation, and every 24 h 
thereafter, five larvae were selected at random from each 
treatment group and tested for haemolymph burden exactly 
as previously described [19].
Phagocytosis assays
The method was adapted from Mandato et al. [20]. Lar-
vae were chilled at 4 °C for 15 min prior to injection with 
75 μL of Galleria saline (GS; 186 mM NaCl, 13 mM KCl, 
10 mM HEPES, 1 mM NaHCO3, 2 mM CaCl2; pH 6.8) 
saturated with phenylthiol urea (PTU). Haemolymph was 
collected from 5 larvae per assayed treatment via amputa-
tion of the terminal thoracic prolegs. The haemolymph was 
centrifuged 5 min at 500 g and the haemocytes resuspended 
in GIM (Grace’s Insect Medium) saturated with PTU and 
dexamethasone 21-phosphate disodium at 5 mg/mL or water 
for the untreated control. Haemocyte viability was measured 
by counting haemocytes that exclude Trypan blue (0.02 % 
in PBS) using a haemocytometer exactly as described previ-
ously [20]. 250 μL of this suspension was placed in separate 
poly (2-hydroxyethyl methacrylate)-coated wells in 24-well 
culture plates (Cellstar®, Greiner bio-one, Frickenhausen, 
Germany). After 15 min, inactivated fluorescein (FITC)-
labelled E. coli K12 Bioparticles® (ThermoFisher Scientific, 
Waltham, MA, USA), 1.0 × 108 lyophilised cells per mL 
resuspended in GS + PTU, were added and incubated at 
37 °C for 1 and 2 h with gentle agitation. Haemocytes were 
quantified using a haemocytometer, and the number of fluo-
rescent bacteria added was calculated such that that the pro-
portion of bacteria to haemocytes was approximately 50:1. 
The assay was stopped by addition of 1 mL of 3.7 % formal-
dehyde in GS. The fixed haemocytes were then pelleted at 
500 g for 4 min and washed with GS to remove excess fluo-
rescent bacteria prior to a 1:1 dilution in glycerol and dis-
pensing on glass microscope slides. Haemocytes and fluores-
cent E. coli were viewed at 40× magnification using a Delta 
Vision microscope (Applied Precision, Issaquah, Wash., 
USA) using differential interference contrast and filters for 
FITC (excitation 490 nm/emission 528 nm). Composite 
images were captured of optical slices through each haemo-
cyte, and internalised fluorescent bacteria were counted. For 
each time point tested, phagocytosed E. coli from at least 30 
haemocytes, from at least two replicate experiments, were 
counted.
Results
The pathogenicity of some clinical isolates of K. 
pneumoniae or E. coli in G. mellonella larvae is 
dependent on high inoculum numbers and cannot be 
attributed specifically to infection by live bacteria
The effect of infection with K. pneumoniae and E. coli 
strains on survival of G. mellonella is shown in Fig. 1. 
There was variation between all the strains in the inocu-
lum size required to kill the majority of the larval popula-
tion, but, supporting previous studies [8–15], the inoculum 
size required to kill the majority of infected larvae 24 h 
post-infection was comparable to that reported for different 
strains of the same organisms. For all bacterial strains, larval 
survival over 96 h was reduced in a dose-dependent manner 
as the inoculum numbers increased. Notably, infection with 
heat-killed inocula of each strain at the highest dose tested 
induced variable lethality. For example, infection with 
either heat-killed K. pneumoniae NCTC9633 (4.0 × 106 per 
larva) or E. coli NCTC12241 (1.1 × 106 per larva) killed 
approximately 10 % of the population after 96 h, whereas 
heat-killed K. pneumoniae NCTC13438 (1.5 × 105 per 
larva) or E. coli NCTC13353 (7.8 × 106 per larva) killed 
approximately 50 and 40 %, respectively, after 96 h (Fig. 1). 
To investigate this further, identical heat-killed inocula of 
K. pneumoniae NCTC13438 and E. coli NCTC13353 that 
were subsequently filter-sterilised and then injected into 
larvae had no detrimental effect on larval survival (data not 
shown; p > 0.05, log-rank test). Similarly, viable inocula of 
both strains that were filter-sterilised prior to injection also 
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had no detrimental effect on larval survival (data not shown; 
p > 0.05, log-rank test). These results indicate that larval 
death induced by the heat-killed cells was due to the pres-
ence of these dead cells and not because of any secreted, or 
released, virulence factors present in the medium.
In conclusion, at the high inoculum levels of K. pneu-
moniae NCTC13438 and E. coli NCTC13353 required to 
kill greater than 90 % of the larval population, bacterial 
pathogenesis cannot be attributed solely to infection by live 
bacteria because some toxicity is induced simply by the 
presence of an unknown virulence factor(s) associated with 
dead cells. Thus, for these particular bacterial strains, G. 
mellonella larvae do not constitute an ideal infection model.
Treatment with dexamethasone 21‑phosphate inhibits 
phagocytosis and sensitises G. mellonella larvae 
to infection by K. pneumoniae or E. coli
Dexamethasone is a glucocorticoid anti-inflammatory drug 
that is used extensively in human medicine. Research has 
Fig. 1  Effect of increasing inoculum dose of live K. pneumoniae 
NCTC9633 (a) or NCTC13438 (c) and E. coli NCTC12241 (b) or 
NCTC13353 (d) on the survival of G. mellonella larvae during incu-
bation at 37 °C for 96 h. Numbers in the legend indicate the inoculum 
size in cells per larva. For all strains, the effect of heat-killed (h.k.) 
bacterial inocula is also shown. No significant mortality was observed 
in an unmanipulated group (data not shown) or in the uninfected 
group sham-infected with sterile PBS. With all treatment groups not 
labelled with tilde, survival was significantly reduced compared to 
the group sham-infected with PBS (p < 0.05, log-rank test with Holm 
correction for multiple comparisons); n = 45 (pooled from replicate 
experiments)
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shown that dexamethasone also has immunomodulatory 
activity in G. mellonella larvae by inhibiting phagocyto-
sis in vitro and prophenoloxidase activation in vivo [20]. 
Mandato et al. [20] administered water insoluble dexa-
methasone dissolved in ethanol to larvae. Here, the effect 
of dexamethasone 21-phosphate, the soluble form of the 
drug used in human medicine, was measured to determine 
whether it too could induce immunosuppression in G. mel-
lonella larvae and whether it could be used to reduce the 
inoculum size of E. coli or K. pneumoniae required to 
cause significant lethality, thus improving the specificity of 
this infection model for these organisms.
Trial experiments determined the optimal exposure 
time and doses of dexamethasone 21-phosphate (data 
not shown). The effect of a 10-min exposure to 80 and 
200 μg per larva doses of dexamethasone 21-phosphate 
prior to bacterial infection with E. coli or K. pneumoniae 
on survival of G. mellonella larvae is shown in Fig. 2. 
For each bacterial strain tested, deliberately small inocu-
lum numbers were selected for infection to easily identify 
any increases in lethality that occurred due to exposure 
to dexamethasone. For all strains, prior treatment with 
dexamethasone, compared with sterile water, resulted in 
significantly increased lethality of infection of an identi-
cal inoculum. The increase in mortality also occurred in a 
dose-dependent manner for all strains, apart from infection 
with K. pneumoniae NCTC9633, where the higher dose 
of 200 μg per larva dexamethasone induced no additional 
larval mortality over that induced by the 80 μg per larva 
dose.
Fig. 2  Effect of an increasing dose of dexamethasone 21-phosphate 
(DEX; 80 or 200 μg per larva) on the survival of G. mellonella lar-
vae infected with K. pneumoniae NCTC9633 (a) or NCTC13438 (c) 
and E. coli NCTC12241 (b) or NCTC13353 (d) during incubation at 
37 °C for 96 h. Numbers in the legend indicate the bacterial inoculum 
size in cells per larva. The control treatment groups labelled ‘infec-
tion only’ were injected with sterile water in place of dexamethasone 
21-phosphate. Dexamethasone 21-phosphate or sterile water was 
administered to the larvae 10 min prior to infection with live bacteria. 
Asterisk indicates a group with significantly reduced survival com-
pared to the control treated with water (p < 0.05, log-rank test with 
Holm correction for multiple comparisons); n = 30 (pooled from 
duplicate experiments)
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Following this, experiments determined the effect of 
increasing the inoculum size of infecting bacteria after 
prior treatment (10 min) with a fixed dose of dexametha-
sone 21-phosphate (Fig. 3). As expected, larval groups 
exposed to water, or dexamethasone (200 μg per larva), 
for 10 min prior to infection showed significantly increased 
mortality in a dose-dependent manner as the inoculum 
size of all strains increased. Notably, this inoculum-size-
dependent lethality was significantly enhanced in larvae 
that had been pre-treated with dexamethasone (200 μg per 
larva) for 10 min prior to infection compared to the control 
groups treated with sterile water.
Importantly, at the concentrations tested, dexamethasone 
21-phosphate treatment alone had no detrimental effects on 
G. mellonella larvae, thus ruling out the possibility that the 
enhanced lethality of infection induced by treatment with 
the compound could be explained by a non-specific toxic 
effect (data not shown; p > 0.05, log-rank test).
To confirm that the enhanced lethality of infection 
induced by exposure to dexamethasone 21-phosphate was 
due to a specific immunosuppressive effect, and whether 
the compound inhibits phagocytosis in G. mellonella simi-
lar to pure dexamethasone [20], phagocytosis assays were 
carried out. The effect of a 1- or 2 h incubation with 5 mg/
mL dexamethasone 21-phosphate on phagocytosis in vitro 
of FITC-labelled E. coli by G. mellonella haemocytes 
is shown in Fig. 4. This concentration was selected after 
trial experiments with a range of concentrations (data not 
shown).
Figure 4a shows a representative image of a single G. 
mellonella haemocyte with phagocytosed FITC-labelled 
E. coli K12 taken after 1 h incubation at 37 °C. Bacteria 
are visible inside the haemocyte and were counted after 
studying images of optical slices through the haemocyte. 
In control experiments (treated with water), the propor-
tion of haemocytes that contained phagocytosed E. coli 
was approximately 25 % after 1 h and 30 % after 2 h 
(Fig. 4b). Exposure to 5 mg/mL dexamethasone 21-phos-
phate reduced this to approximately 12 and 15 % after 1 
and 2 h, respectively (Fig. 4b). The observed inhibition of 
phagocytosis was not due to a toxic effect of dexametha-
sone 21-phosphate because measurement of haemocyte 
viability revealed no significant detrimental effect of expo-
sure to the compound under the conditions tested (data not 
shown).
The effect of immunosuppressive treatment with dexa-
methasone 21-phosphate on the proliferation of bacte-
ria in G. mellonella larvae over 96 h was measured via a 
bacterial burden assay (Fig. 5). Inoculum sizes of E. coli 
NCTC13353 (1.0 × 106 cells per larva) and K. pneumoniae 
Fig. 3  Effect of pre-treatment 
with dexamethasone 21-phos-
phate (DEX; 200 μg per larva) 
and subsequent infection with 
increasing inoculum sizes of 
K. pneumoniae NCTC9633 
(a) or NCTC13438 (c) and 
E. coli NCTC12241 (b) or 
NCTC13353 (d) on the survival 
of G. mellonella larvae after 
96 h at 37 °C. Groups treated 
with dexamethasone 21-phos-
phate were compared to con-
trols treated with sterile water. 
Dexamethasone 21-phosphate 
or water was administered to the 
larvae 10 min prior to infection 
with live bacteria. Asterisk indi-
cates a group with significantly 
reduced survival compared to 
the control treated with water 
(p < 0.05, log-rank test with 
Holm correction for multiple 
comparisons); n = 30 (pooled 
from duplicate experiments). 
±Standard deviation error bars 
are shown for each treatment 
group
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NCTC13438 (5.6 × 104 cells per larva) were chosen that 
induced large differences in levels of mortality in popula-
tions that were pre-treated with water compared to 200 μg 
per larva of dexamethasone 21-phosphate (Fig. 3). In con-
trol populations of larvae, infected with either the E. coli or 
the K. pneumoniae strain after pre-treatment with water, the 
bacterial population size did not increase over the 96 h dura-
tion of the experiment (Fig. 5). This implies that the innate 
immune system of the larvae prevents the bacteria from pro-
liferating and reflects the low levels of mortality observed 
under these conditions (Fig. 3). In contrast, pre-treatment 
with 80 or 200 μg per larva of dexamethasone prior to infec-
tion resulted in significant increases in bacterial numbers, of 
either the E. coli or the K. pneumoniae strain, inside the lar-
vae after just 24 h (Fig. 5). Post-24 h, there is some fluctua-
tion in total bacterial numbers detected that may be due to 
the random sampling of the five larvae from the total popu-
lation for each time point. Nonetheless, this proliferation of 
bacteria correlated with the enhanced mortality of infected 
larvae induced upon exposure to an identical dose of dexa-
methasone observed previously (Fig. 3).
To conclude, treatment of G. mellonella larvae with 
dexamethasone 21-phosphate enhanced the lethality 
induced by infection with E. coli or K. pneumoniae in a 
dose- and inoculum size-dependent manner. The enhanced 
lethality observed correlated with proliferation of bacte-
ria in the larvae that could be attributed to dexamethasone 
inhibiting haemocyte phagocytosis and thus acting as an 
immunosuppressant.
The efficacy of antibiotic therapy versus K. pneumoniae 
or E. coli infection is reduced in larvae treated 
with dexamethasone 21‑phosphate
The MICs of ceftazidime for the four strains used in this 
work were: E. coli NCTC12241 and NCTC13353, 0.25 and 
Fig. 4  a Representative image of a single G. mellonella haemocyte 
after 1 h incubation at 37 °C with inactivated FITC-labelled E. coli 
K12. Images are shown with differential interference contrast (DIC), 
filters for FITC (excitation 490 nm/emission 528 nm) and a merged 
DIC/FITC image. The merged image represents a central 0.2 μM 
optical slice through the haemocyte allowing precise counting of 
internalised bacteria. Haemocytes and fluorescent E. coli were viewed 
at 40× magnification. b Effect of a 1- or 2 h incubation at 37 °C with 
dexamethasone 21-phosphate (DEX; 5 mg/mL) on the phagocytosis 
of inactivated fluorescein (FITC)-labelled E. coli K12 by purified 
haemocytes from G. mellonella larvae. Haemocytes and fluorescent 
E. coli were viewed using differential interference contrast or fluo-
rescence microscopy at 40× magnification, and bacteria inside the 
haemocytes were counted. For each time point tested, phagocytosed 
E. coli from at least 30 haemocytes, from at least two replicate exper-
iments, were counted per slide. ±SE bars are drawn for each treat-
ment group
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64 mg/L, respectively; and K. pneumoniae NCTC9633 and 
NCTC13438, 0.5 and ≥512 mg/L, respectively. The effect 
of treatment with ceftazidime, with or without prior expo-
sure to dexamethasone-21-phosphate, on larvae infected 
with the two sensitive strains, E. coli NCTC12241 and K. 
pneumoniae NCTC9633, is shown in Fig. 6. 2 h post-infec-
tion, the larvae were treated with either PBS or increasing 
doses of ceftazidime (10 or 25 mg/kg for K. pneumoniae 
NCTC9633; and 1 or 2 mg/kg for E. coli NCTC12241). 
Supporting the previous observations, in the control groups 
administered PBS rather than the antibiotic, exposure to 
dexamethasone 21-phosphate (200 μg per larva) prior 
to infection resulted in enhanced lethality of both strains 
compared to treatment with water. However, in control 
groups treated with water in the absence of dexamethasone 
21-phosphate, administration of ceftazidime significantly 
improved survival of larvae, infected with either strain, in 
a dose-dependent manner. In comparison, after prior expo-
sure to dexamethasone 21-phosphate, the efficacy of identi-
cal doses of ceftazidime was significantly reduced.
In summary, prior exposure to the immunosuppressant 
dexamethasone 21-phosphate not only enhances G. mel-
lonella lethality induced by infection with E. coli or K. 
pneumoniae but also reduces the efficacy of a normally 
effective antibiotic treatment.
Discussion
The sensitivity of G. mellonella larvae to infection by the 
E. coli or K. pneumoniae strains in this work compares 
favourably with that identified in previous studies [8–11, 
13–15]. For example, between 1.0 × 105 and 5.0 × 106 
CFU per larva are required for E. coli to induce significant 
mortality [13–15] and between 1.0 × 105 and 1.0 × 106 
CFU per larva for K. pneumoniae [8–11]. In contrast, dif-
ferent strains of Pseudomonas aeruginosa induced signifi-
cant lethality of G. mellonella after infection with as few 
as 25 cells per larva [16, 17]. This implies that either the 
innate immune system of G. mellonella is better adapted 
to combat K. pneumoniae and E. coli, or these pathogens 
are less virulent than P. aeruginosa in the larvae, or a com-
bination of both factors could contribute to the observed 
differences.
In response to bacterial infection, the immune system of 
G. mellonella forms melanotic nodules whose formation 
is regulated by signalling molecules termed eicosanoids. 
Nodules form when insect haemocytes degranulate upon 
contact with bacteria followed by activation of the pro-
phenoloxidase cascade which results in the formation of 
melanin around the bacteria. Subsequently, a capsule forms 
around the sequestered bacteria in the developing nodule 
due to attachment and spreading of further haemocytes 
followed by the commencement of phagocytic activity to 
remove and destroy the bacteria [21]. Mandato et al. [20] 
showed that the eicosanoid biosynthesis inhibitor dexa-
methasone inhibited prophenoloxidase activation in vivo 
and haemocyte spreading and phagocytosis in vitro. Sup-
porting this, a recent study showed that administration of 
dexamethasone repressed G. mellonella innate immunity in 
a similar fashion to injected entomopathogenic nematode 
cuticles [22].
This work has shown that the anti-inflammatory 
drug dexamethasone 21-phosphate also acts as an 
Fig. 5  Effect of pre-treatment with dexamethasone 21-phos-
phate (DEX; 80 or 200 μg per larva) and subsequent infection with 
1.0 × 106 cells per larva of E. coli NCTC13353 (a) or 5.6 × 104 cells 
per larva of K. pneumoniae NCTC13438 (b) on larval burden of bac-
teria during incubation at 37 °C for 96 h. Larvae treated with dexa-
methasone 21-phosphate were compared to controls treated with ster-
ile water. Dexamethasone 21-phosphate or water was administered to 
the larvae 10 min prior to infection with live bacteria. Larval burden 
was determined from 5 individual larvae every 24 h. The data shown 
is from duplicate experiments and the error bars indicate the ± stand-
ard error
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immunosuppressant in G. mellonella larvae. Larvae 
exposed to the drug become more sensitive to infection 
by E. coli and K. pneumoniae and die more rapidly than 
untreated equivalents. This enhanced lethality occurs due 
to the uncontrolled proliferation of bacteria within the 
infected larvae that can be at least partially attributed to the 
inhibitory effect treatment with the drug has on haemocyte 
phagocytosis. Supporting these findings, studies using the 
alternative immunosuppressant drugs, cyclosporin A [23] 
and hydrocortisone [24], also enhanced the lethality of bac-
terial infections, by Pseudomonas aeruginosa and Entero-
bacter cloacae, respectively, in G. mellonella larvae.
Dexamethasone 21-phosphate has the advantage of 
being water soluble and easier to administer then dexa-
methasone which is only soluble at use concentrations in 
organic solvents, such as ethanol or dimethyl sulphoxide, 
which, in our hands, had toxic side effects on G. mellonella 
larvae (data not shown).
Doses of dexamethasone phosphate used in humans are 
variable depending on the underlying condition and sever-
ity of disease. For sepsis, doses between 0.3 and 30 mg/
kg have been administered in a range of published trials 
(reviewed in [25]). The highest effective dose adminis-
tered in this work (200 μg per larva) equates to a dose of 
800 mg/kg, indicating that the immunosuppressive effect 
of dexamethasone phosphate is far more potent in human 
patients than in G. mellonella larvae.
Successful application of an immunosuppressant with 
the G. mellonella infection model is significant because 
immunosuppression may facilitate studies on infection and 
Fig. 6  Effect of ceftazidime 
treatment on survival of G. 
mellonella larvae pre-exposed 
to dexamethasone 21-phos-
phate (DEX; 200 μg per 
larva) prior to infection with 
2.9 × 105 cells per larva of K. 
pneumoniae NCTC9633 (a, 
b), or 2.5 × 104 cells per larva 
of E. coli NCTC12241 (c, d). 
E. coli NCTC12241 and K. 
pneumoniae NCTC9633 do not 
possess β-lactamases and were 
sensitive to ceftazidime in vitro 
with MIC values of 0.25 and 
0.5 mg/L, respectively. Survival 
was measured during incubation 
at 37 °C for 96 h, and dexa-
methasone 21-phosphate-treated 
groups (b, d) were compared to 
controls treated with water (a, 
c). Dexamethasone 21-phos-
phate or water was administered 
to the larvae 10 min prior to 
infection with live bacteria. 
A single dose of ceftazidime 
(CAZ) was administered 2 h 
post-infection: 10 and 25 mg/kg 
for K. pneumoniae NCTC9633 
(a, b), and 1 and 2 mg/kg for 
E. coli NCTC12241 (c, d). 
Asterisk indicates a group with 
significantly enhanced survival 
compared to the infected control 
treated with PBS (p < 0.05, log-
rank test). n = 30 (pooled from 
duplicate experiments)
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treatment of alternative human pathogens that have low 
virulence or do not normally induce acute infections in 
this invertebrate [26]. Furthermore, the use of immunosup-
pression will better mimic the physiological state of many 
human patients that suffer from hospital-acquired infections 
caused by organisms such as E. coli and K. pneumoniae 
and thus improve the clinical relevance of this invertebrate 
model. Finally, this work has shown that immunosuppres-
sion can be used to improve the specificity of infection in 
G. mellonella. For example, as discussed earlier, infections 
with E. coli and K. pneumoniae require high inoculum num-
bers to induce lethality of the larvae. As a consequence of 
this, infections with identical inocula that were heat-killed 
induced high levels of larval mortality that could not be 
attributed solely to infection by live bacteria but were also 
due to the presence of toxic components of the dead bac-
teria. Treatment with dexamethasone 21-phosphate allowed 
infections with smaller inoculum sizes of both E. coli and 
K. pneumoniae to induce substantial larval lethality where 
equivalent heat-killed inocula did not induce significant 
pathogenicity. This implies that the specificity of infection 
of G. mellonella can be significantly improved by using 
dexamethasone phosphate to alleviate the need to use high 
cell number inocula of bacterial species such as E. coli and 
K. pneumoniae. A possible explanation for the observed 
toxicity of the dead cells may be due to the induction of a 
pro-inflammatory effect analogous to that seen with Gram-
negative sepsis in humans, but this would require additional 
investigation that is outside the scope of this study.
Distinct from administering a specific drug to induce 
immunosuppression, but corroborating this finding, 
enhanced susceptibility of G. mellonella larvae to micro-
bial infection has been reported after exposure to different 
stress factors that impair aspects of innate immunity. For 
example, infection by Candida albicans or Staphylococ-
cus aureus induced greater larval mortality after prolonged 
incubation over a 10-week period at 15 °C that was attrib-
uted to a combination of a decline in certain metabolic 
pathways and changes in the relative abundance of haemo-
cytes [27]. Similarly, nutrient deprivation of larvae also has 
immunosuppressive effects and results in lower haemocyte 
density and a reduction in the expression of antimicrobial 
peptides leading to increased susceptibility to C. albicans 
infection [28].
In the clinical setting, the co-administration of anti-
inflammatory drugs with antibiotics remains controversial. 
Adjunctive treatment with corticosteroids such as dexa-
methasone is used to decrease inflammation and mortal-
ity in bacterial meningitis or sepsis [25, 29]. However, 
evidence has been presented that this could contribute to 
failure of antibiotic therapy [30, 31]. In this work, adminis-
tration of ceftazidime to G. mellonella larvae infected with 
susceptible strains of E. coli and K. pneumoniae resulted in 
enhanced survival. However, the efficacy of the antibiotic 
was reduced in immunosuppressed larvae that had been 
treated with dexamethasone 21-phosphate prior to infec-
tion. This could be explained by the immunosuppressant 
drug interfering with the inhibitory action of the antibi-
otic, or because the immunosuppressant inhibits aspects of 
innate immunity, and as a consequence allows the infecting 
bacteria to proliferate (as shown in this study), an identical 
dose of antibiotic would not be as efficacious as it would 
be in larvae not immunosuppressed. Alternatively, dexa-
methasone can induce overexpression of tolC, repression of 
OmpF, stimulate antibiotic efflux and ultimately reduce the 
susceptibility of E. coli to antibiotics in vitro [32].
The reduction in antibiotic efficacy seen with immuno-
suppressive therapy merits further investigation with the G. 
mellonella model to help clarify the relationship between 
the immune system and antibiotic treatment to clearance 
of bacteria and the relative contributions of each to abro-
gation of infection. Notably, this could have some clinical 
relevance to the adjunctive use of anti-inflammatory drugs 
with antibiotics that is used to tackle some serious bacterial 
infections.
To conclude, the demonstration of an effective immuno-
suppressant regimen in the G. mellonella infection model 
shown here should facilitate additional studies on novel 
treatments to combat MDR Gram –ve bacteria, such as E. 
coli and K. pneumoniae, that cause serious infections in 
hospitals caring for already severely ill patients and further 
develops G. mellonella as a serious alternative model host.
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